Gastric Bypass: Roux-en-Y, OAGB, Diabetes and Risks

By Vireon Medical Editorial TeamFirst published 5 November 2026Evidence checked through 5 November 2026

Short answer

Gastric bypass is a weight loss operation that creates a small stomach pouch and connects it to the small intestine, so food skips most of the stomach and the first part of the intestine.³ It is considered for obesity, including when type 2 diabetes is present, and is often preferred to a sleeve when reflux is a problem.¹¹⁰ Its trade-offs include dumping syndrome, ulcers at the join, bowel obstruction, a higher risk of vitamin and iron shortage, and changes in how the body handles alcohol.³⁴ Whether it is a reasonable choice depends on your health conditions, medicines, habits and ability to attend lifelong follow-up, so individual assessment matters.

Decision snapshot

Question	What the evidence and guidance say
Type of procedure	Usually keyhole surgery under general anaesthesia³
Usual hospital stay	1 to 3 days¹²
Return to normal activities	Gradually, from about 4 to 6 weeks¹²
Weight loss compared with a sleeve	Slightly greater in randomised trials⁸⁹
Main long-term issues	Dumping, ulcers, bowel obstruction, deficiencies, alcohol sensitivity³⁵
Follow-up	At least 2 years with a bariatric service, then at least yearly checks for life²
Reversible?	Difficult to reverse⁴

Summary only. Details and limitations are explained below.

On this page

What gastric bypass is and how it works
What may be causing the concern
Who may be considered
Alternatives, including the sleeve
Procedure, preparation and anaesthesia
Recovery and results timeline
How long results last
Pain and comfort
Risks and complications
How strong is the evidence?
Roux-en-Y and one-anastomosis variants
Cost drivers and what a quote should include
Frequently asked questions
Sources

What gastric bypass is and how it works

In a Roux-en-Y gastric bypass (RYGB), the surgeon creates a pouch from the top of the stomach about the size of a walnut. The small intestine is divided and its lower part is joined to the pouch; the upper part is reconnected further down so digestive juices can still mix with food.³⁴

Food therefore bypasses most of the stomach and the first section of the small intestine. Less food fits, fewer calories are absorbed, and gut hormones, bacteria and other signals that affect appetite and metabolism change.⁴ These hormonal effects are one reason bypass is studied as a treatment for type 2 diabetes, not only for weight.

The ASMBS (American Society for Metabolic and Bariatric Surgery) and IFSO (International Federation for the Surgery of Obesity and Metabolic Disorders) describe RYGB and sleeve gastrectomy as the dominant operations, each with well-studied mid- and long-term outcomes.¹

A sleeve gastrectomy removes most of the stomach and leaves a narrow tube; a Roux-en-Y gastric bypass creates a small pouch joined to the small intestine, so food bypasses the rest of the stomach and the duodenum, whose digestive juices rejoin the food further down. Simplified diagram, not to scale.

What may be causing the concern

Obesity and type 2 diabetes have many contributors: genes, eating patterns, sleep, mental health, activity, environment, some medicines and some hormonal conditions. Surgery changes the gut; it does not treat a medicine side effect, an underactive thyroid or an eating disorder.

NICE (the National Institute for Health and Care Excellence) therefore requires assessment by a specialist weight management service with medical, nutritional, psychological and surgical input before surgery.²

What it may change

Body weight, usually substantially, with wide individual variation.⁷
Type 2 diabetes control; ASMBS/IFSO advise considering metabolic surgery for metabolic disease even at a BMI of 30 to 34.9 kg/m2.¹
Reflux, which bypass tends to help rather than worsen.⁹¹⁰

What it will not change

It does not end the need for dietary change and activity; weight can be regained.³
Diabetes does not go into remission for everyone; in one 10-year trial about a third of people with diabetes were in remission after bypass.⁹
It does not remove excess skin after weight loss.¹³

Who may be considered

Guidance	Thresholds for considering surgery
ASMBS/IFSO 2022	Recommended at body mass index (BMI) 35 kg/m2 or more; considered at 30 to 34.9 kg/m2 with metabolic disease; offered from 27.5 kg/m2 in Asian populations. No upper age limit.¹
NICE (England)	BMI 40 kg/m2 or more, or 35 to 39.9 kg/m2 with a significant health condition, plus agreement to long-term follow-up. Expedited assessment for recent-onset type 2 diabetes at BMI 35 or more; considered at 30 to 34.9. Thresholds are 2.5 kg/m2 lower for several ethnic family backgrounds.²

Thresholds open an assessment; they do not decide it.

Bypass may be favoured over a sleeve when reflux disease is confirmed or severe; the ASMBS states such patients are generally better served by RYGB.¹⁰ NICE asks that the procedure is chosen jointly with the person.²

Who may not benefit or may face additional risk

People with a history of problem drinking, because bypass changes alcohol absorption and may increase alcohol-related problems.⁴⁵
People who cannot take supplements or attend blood tests, since vitamin and iron shortage is more likely than after a sleeve.⁴
People planning pregnancy within 12 to 18 months.¹²

When a responsible clinician may advise against it

When the person cannot commit to long-term follow-up, which NICE makes part of the referral criteria.²
When assessment finds medical, nutritional or psychological issues that need treatment first.²
When frailty makes surgery riskier; ASMBS/IFSO recommend assessing frailty, which predicts complications better than age.¹

Alternatives, including the sleeve

Structured diet, activity and behavioural support come first, and NICE expects these before medicines.² Weight loss medicines such as semaglutide and tirzepatide are options under NICE guidance; semaglutide is prescribed within specialist services, and tirzepatide in primary care or a specialist service.² The main surgical alternative is the sleeve gastrectomy.

Outcome	Gastric bypass	Sleeve gastrectomy
BMI loss, randomised trials	Slightly greater at 1 and 3 years	Slightly less⁸
Median excess weight loss at 10 years (SLEEVEPASS)	50.7%	43.5%⁹
Type 2 diabetes remission	No significant difference in a meta-analysis of trials; 33% vs 26% at 10 years in SLEEVEPASS⁸⁹
Oesophagitis at 10 years	7%	31%⁹
Reoperation by 10 years (SLEEVEPASS)	18.5%	15.7%⁹
Vitamin and iron shortage	More likely	Less likely⁴
Changes to intestine	Yes	No⁴

Excess weight loss (EWL) is the share of weight above a BMI of 25 that is lost. Reoperation and diabetes differences in SLEEVEPASS were not statistically significant.

No treatment is a legitimate option

Not having surgery, or postponing it while trying other approaches, is a valid choice. Bypass is difficult to reverse and commits you to lifelong supplements and monitoring.

Procedure, preparation and anaesthesia

Preparation includes medical, nutritional and psychological assessment, and a discussion of long-term requirements and risks.² The ASMBS considers a pre-operative gastroscopy (camera test of the gullet and stomach) justifiable at the surgeon’s discretion.¹⁰

The operation is performed under general anaesthesia, usually by keyhole surgery, and takes a few hours.³

Recovery and results timeline

Most people go home 1 to 3 days after surgery.¹² The NHS describes fluids in weeks 1 to 2, runny foods in weeks 3 to 4, soft foods in weeks 5 to 8, and a gradual return to a balanced diet from week 8, eaten slowly in small amounts. Normal activities usually resume from 4 to 6 weeks.¹²

Nutrient blood tests are recommended at 3, 6 and 12 months, then at least once a year.¹¹ Specialist follow-up should last at least 2 years, followed by lifelong yearly reviews.²

How long results last

A systematic review of results at 10 years or more included 18 gastric bypass studies, with a weighted mean excess weight loss of 56.7%.⁷ Study quality was low and many patients were lost to follow-up.

Weight can be regained, especially without lasting changes to diet and activity.³ Within 5 years, about a third of people need a further intervention, surgery or hospital stay, more often after bypass than sleeve.⁵

Pain and comfort

You are asleep during the operation.³ Afterwards, wound and abdominal discomfort is managed with pain relief in hospital and at home. Ask your team which pain medicines are safe for you in the long term.

Abdominal pain that is severe, or that comes back months or years later, is not something to wait out: it can signal an ulcer or bowel obstruction and needs assessment.³¹³

Risks and complications

Expected temporary effects

Wound soreness, tiredness and difficulty eating more than small amounts are expected early on, which is why the diet is built up in stages.¹² Diarrhoea can occur.³

Recognised complications

Dumping syndrome: food moving too quickly into the intestine. Early dumping starts within 30 minutes of eating; late dumping 1 to 3 hours after. Symptoms include diarrhoea, nausea, light-headedness and tiredness. Smaller, more frequent meals with more protein are the first step, and mild symptoms often improve with time.⁶
Low blood sugar (hypoglycaemia).³
Marginal ulcer: an ulcer at the join between the pouch and intestine. Ulcers and stomach perforation are listed among long-term risks.³
Bowel obstruction and internal hernia (bowel trapped inside the abdomen after the rerouting): bowel obstruction and hernias are recognised long-term risks.³¹³
Micronutrient deficiencies: iron, folate, B12 and vitamin D deficiency are common; zinc, copper and selenium can fall, and vitamin A may need extra attention after RYGB. B12 deficiency can cause irreversible nerve damage.¹¹ Anaemia and osteoporosis can follow.⁵
Alcohol sensitivity: bypass may change how alcohol is absorbed and broken down and may increase the risk of alcohol use disorder.⁴⁵
Other: gallstones, kidney stones, blood clots and wound infection.³¹³

Rare serious complications

Leaks from the joins, bleeding, blood clots in the lungs and stomach perforation can occur, and complications can rarely be fatal.³¹³ Thiamine (vitamin B1) deficiency after prolonged vomiting can cause confusion, unsteadiness and, untreated, coma.¹¹

Urgent warning signs

The NHS advises calling 999 or going to A&E for:¹³

Severe tummy pain.
Difficulty breathing or chest pain with pain and swelling in a leg.
Vomiting blood, or vomit that looks like coffee grounds; heavy bleeding from the bottom.

Seek urgent same-day advice for a high temperature, fast heartbeat, fast breathing, tummy pain, difficulty swallowing or regular vomiting.¹³

How strong is the evidence?

Claim	Vireon assessment	What supports it	Important limitation
Bypass produces durable weight loss beyond 10 years	Moderate	Systematic review of 18 bypass studies⁷	Low-quality studies; loss to follow-up
Bypass gives slightly more weight loss than a sleeve	Moderate	Meta-analysis of 33 trials; 10-year trial⁸⁹	Difference is small; sparse trial data beyond 5 years
Bypass and sleeve give similar diabetes remission	Moderate	Meta-analysis of trials; SLEEVEPASS⁸⁹	Small diabetes subgroups
Less oesophagitis after bypass than sleeve	Strong	10-year randomised trial; ASMBS position⁹¹⁰	One large trial; reflux definitions vary
Higher risk of alcohol-related problems	Limited	National health institute summary⁴⁵	Observational research; size of risk not given here
Rates of marginal ulcer and internal hernia	Uncertain incidence	Recognised in clinical sources³	Rates vary by technique and reporting
One-anastomosis bypass long-term weight loss	Insufficient	Two studies at 10 years or more⁷	More long-term data needed

Evidence assessed on 5 November 2026.

Most long-term bypass data come from observational cohorts with missing follow-up. Randomised trials comparing bypass with a sleeve are informative but relatively small, and direct comparisons with newer medicines are scarce.

Roux-en-Y and one-anastomosis variants

RYGB uses two joins: pouch to intestine, and a second join further down the intestine. A one-anastomosis gastric bypass (OAGB, sometimes called mini gastric bypass) uses a longer pouch and a single join to a loop of intestine.

OAGB has fewer long-term data. A systematic review found only two OAGB studies reporting results at 10 years or more and called for more.⁷ IFSO has published a position statement on OAGB, which it plans to revisit as higher-quality studies emerge.¹⁴ Ask which variant is proposed, why, and how reflux and nutrition will be monitored.

Red flag: little or no expert assessment, discussion and counselling before surgery; UK societies warn this can happen abroad.¹⁵
Red flag: no written supplement plan or blood test schedule.
Red flag: the variant is not named in writing, or surgery is scheduled before you meet the surgeon.

Cost drivers and what a quote should include

Cost depends on the hospital and team, length of stay, pre-operative tests, operating time, and access to intensive care. Lifelong supplements, B12 injections and blood tests add ongoing costs.¹¹

Which variant is planned and which assessments are included.
Nights in hospital, and what happens if a longer stay is needed.
How complications, re-operation and readmission are handled and paid for.
What follow-up is included, for how long, and the written discharge summary.

If you are travelling for treatment

UK societies advise seeing a UK surgeon before travelling and warn that care for complications may need to be paid for by the patient.¹⁵
Long-distance travel soon after surgery carries a risk of blood clots; agree with the team when flying is reasonable.¹⁵
NHS hospitals have treated leaks, malnutrition and long admissions after surgery abroad.¹⁶
Some problems, such as B12 deficiency, can appear years later, so arrange specialist follow-up at home and carry an operation note naming the variant.²¹¹

Questions worth asking a clinician

Why bypass rather than a sleeve or medicines in my case?
Roux-en-Y or one-anastomosis, and why?
How should I recognise dumping, low blood sugar or an ulcer?
Which supplements and injections will I need, and who checks my blood tests?
What should I know about alcohol after surgery?

Frequently asked questions

Does gastric bypass hurt?

You are asleep during surgery, and discomfort afterwards is usually managed with pain relief.³ Severe tummy pain at any stage needs urgent assessment.¹³

When can I return to work, exercise, drive and fly?

The NHS describes a gradual return to normal activities from 4 to 6 weeks.¹² Driving and flying depend on your recovery and your team’s advice; long journeys soon after surgery raise blood clot risk.¹⁵

Will my diabetes go away?

Not necessarily. In the SLEEVEPASS trial, 33% of people with type 2 diabetes were in remission 10 years after bypass.⁹

Can I drink alcohol afterwards?

Bypass may change how alcohol is absorbed and broken down, and the risk of alcohol use disorder may rise.⁴⁵ Discuss limits with your team.

Will I need vitamins for life?

Expect to need them long term. UK guidance recommends a daily complete multivitamin and mineral, extra iron and vitamin D, good calcium intake, and vitamin B12 injections every 3 months, with blood tests at least once a year.¹¹

Bottom line

Gastric bypass offers slightly more weight loss and less reflux than a sleeve, at the cost of more nutritional risk, dumping, ulcers and obstruction. Those trade-offs last for life, so the decision rests as much on follow-up arrangements and alcohol habits as on BMI.

Sources

Eisenberg D, Shikora SA, Aarts E, et al. 2022 American Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO): Indications for Metabolic and Bariatric Surgery. Obesity Surgery; 2023;33(1):3-14. https://doi.org/10.1007/s11695-022-06332-1 (full text: https://link.springer.com/content/pdf/10.1007/s11695-022-06332-1.pdf). Accessed 5 November 2026.
National Institute for Health and Care Excellence. Overweight and obesity management (NG246): Medicines and surgery. NICE; 2025. https://www.nice.org.uk/guidance/NG246/chapter/medicines-and-surgery. Accessed 5 November 2026.
Mayo Clinic. Gastric bypass (Roux-en-Y). Mayo Foundation for Medical Education and Research. https://www.mayoclinic.org/tests-procedures/gastric-bypass-surgery/about/pac-20385189. Accessed 5 November 2026.
National Institute of Diabetes and Digestive and Kidney Diseases. Types of weight-loss surgery. NIDDK; last reviewed September 2020. https://www.niddk.nih.gov/health-information/weight-management/bariatric-surgery/types. Accessed 5 November 2026.
National Institute of Diabetes and Digestive and Kidney Diseases. Weight-loss surgery side effects. NIDDK; last reviewed September 2020. https://www.niddk.nih.gov/health-information/weight-management/bariatric-surgery/side-effects. Accessed 5 November 2026.
National Institute of Diabetes and Digestive and Kidney Diseases. Dumping syndrome. NIDDK; last reviewed January 2019. https://www.niddk.nih.gov/health-information/digestive-diseases/dumping-syndrome. Accessed 5 November 2026.
O’Brien PE, Hindle A, Brennan L, et al. Long-term outcomes after bariatric surgery: a systematic review and meta-analysis of weight loss at 10 or more years for all bariatric procedures and a single-centre review of 20-year outcomes after adjustable gastric banding. Obesity Surgery; 2019;29(1):3-14. https://doi.org/10.1007/s11695-018-3525-0. Accessed 5 November 2026.
Lee Y, Doumouras AG, Yu J, et al. Laparoscopic sleeve gastrectomy versus laparoscopic Roux-en-Y gastric bypass: a systematic review and meta-analysis of weight loss, comorbidities, and biochemical outcomes from randomized controlled trials. Annals of Surgery; 2021;273(1):66-74. https://doi.org/10.1097/SLA.0000000000003671. Accessed 5 November 2026.
Salminen P, Grönroos S, Helmiö M, et al. Effect of laparoscopic sleeve gastrectomy vs Roux-en-Y gastric bypass on weight loss, comorbidities, and reflux at 10 years in adult patients with obesity: the SLEEVEPASS randomized clinical trial. JAMA Surgery; 2022;157(8):656-666. https://doi.org/10.1001/jamasurg.2022.2229 (PubMed: https://pubmed.ncbi.nlm.nih.gov/35731535/). Accessed 5 November 2026.
Campos GM, Mazzini GS, Altieri MS, et al. ASMBS position statement on the rationale for performance of upper gastrointestinal endoscopy before and after metabolic and bariatric surgery. Surgery for Obesity and Related Diseases; 2021;17:837-847. https://doi.org/10.1016/j.soard.2021.03.007 (full text: https://old.asmbs.org/app/uploads/2021/04/PIIS1550728921001404.pdf). Accessed 5 November 2026.
O’Kane M, Parretti HM, Pinkney J, et al. British Obesity and Metabolic Surgery Society guidelines on perioperative and postoperative biochemical monitoring and micronutrient replacement for patients undergoing bariatric surgery: 2020 update. Obesity Reviews; 2020. https://doi.org/10.1111/obr.13087 (full text: https://discovery.ucl.ac.uk/id/eprint/10108215/). Accessed 5 November 2026.
NHS. Recovering from weight loss surgery. NHS website; page last reviewed 5 February 2024. https://www.nhs.uk/tests-and-treatments/weight-loss-surgery/recovering/. Accessed 5 November 2026.
NHS. Complications of weight loss surgery. NHS website; page last reviewed 5 February 2024. https://www.nhs.uk/tests-and-treatments/weight-loss-surgery/complications/. Accessed 5 November 2026.
De Luca M, Piatto G, Merola G, et al. IFSO update position statement on one anastomosis gastric bypass (OAGB). Obesity Surgery; 2021;31(7):3251-3278. https://doi.org/10.1007/s11695-021-05413-x. Accessed 5 November 2026.
British Association of Aesthetic Plastic Surgeons and British Obesity and Metabolic Surgery Society. Joint BAAPS/BOMSS statement on surgical tourism: consult a UK surgeon first. BAAPS; 2023. https://baaps.org.uk/media/press_releases/1874/joint_baapsbomss_statement_on_surgical_tourism__consult_a_uk_surgeon_first. Accessed 5 November 2026.
England C, Bromham N, Needham-Taylor A, et al. Complications and costs to the UK National Health Service due to outward medical tourism for elective surgery: a rapid review. BMJ Open; 2026;16:e109050. https://doi.org/10.1136/bmjopen-2025-109050 (full text: https://orca.cardiff.ac.uk/id/eprint/184036/1/e109050.full.pdf). Accessed 5 November 2026.

Article history

5 November 2026 — First published.